GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 93 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q2 2016. The put-call ratio across all filers is 1.17 and the average weighting 0.4%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $156,946,000 | +1109.5% | 2,304,636 | +467.5% | 0.02% | +1050.0% |
Q2 2022 | $12,976,000 | +102.2% | 406,113 | +119.2% | 0.00% | +100.0% |
Q1 2022 | $6,417,000 | +28.6% | 185,230 | +8.7% | 0.00% | 0.0% |
Q4 2021 | $4,990,000 | +271.3% | 170,456 | +223.3% | 0.00% | – |
Q3 2021 | $1,344,000 | -33.8% | 52,722 | -9.0% | 0.00% | – |
Q2 2021 | $2,029,000 | -93.3% | 57,919 | -92.3% | 0.00% | -100.0% |
Q1 2021 | $30,505,000 | -0.1% | 748,623 | +6.2% | 0.00% | 0.0% |
Q4 2020 | $30,531,000 | -13.8% | 704,945 | +7.4% | 0.00% | -33.3% |
Q3 2020 | $35,408,000 | -24.4% | 656,435 | -11.5% | 0.01% | -33.3% |
Q2 2020 | $46,845,000 | +99.2% | 742,034 | +61.2% | 0.01% | +50.0% |
Q1 2020 | $23,522,000 | -31.9% | 460,383 | +5.9% | 0.01% | 0.0% |
Q4 2019 | $34,553,000 | +65.3% | 434,690 | +0.9% | 0.01% | +50.0% |
Q3 2019 | $20,902,000 | -3.3% | 430,795 | +7.6% | 0.00% | 0.0% |
Q2 2019 | $21,614,000 | +6.9% | 400,466 | +4.8% | 0.00% | 0.0% |
Q1 2019 | $20,223,000 | +32.6% | 382,069 | +2.9% | 0.00% | 0.0% |
Q4 2018 | $15,249,000 | +10.9% | 371,448 | +2.6% | 0.00% | +33.3% |
Q3 2018 | $13,752,000 | -3.0% | 361,865 | +15.4% | 0.00% | 0.0% |
Q2 2018 | $14,179,000 | +163.0% | 313,677 | +180.9% | 0.00% | +200.0% |
Q1 2018 | $5,392,000 | -38.8% | 111,650 | -50.1% | 0.00% | -50.0% |
Q4 2017 | $8,809,000 | +28.4% | 223,879 | -3.8% | 0.00% | 0.0% |
Q3 2017 | $6,862,000 | +6.5% | 232,621 | -1.3% | 0.00% | +100.0% |
Q2 2017 | $6,446,000 | -22.0% | 235,675 | +5.1% | 0.00% | -50.0% |
Q1 2017 | $8,262,000 | +225.3% | 224,207 | +27.5% | 0.00% | +100.0% |
Q4 2016 | $2,540,000 | -40.5% | 175,825 | -5.1% | 0.00% | 0.0% |
Q3 2016 | $4,272,000 | +45.6% | 185,305 | +4.8% | 0.00% | 0.0% |
Q2 2016 | $2,935,000 | -0.5% | 176,855 | -4.9% | 0.00% | 0.0% |
Q1 2016 | $2,950,000 | -51.3% | 186,000 | -0.8% | 0.00% | -50.0% |
Q4 2015 | $6,062,000 | -32.7% | 187,500 | -12.2% | 0.00% | 0.0% |
Q3 2015 | $9,005,000 | – | 213,575 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |